<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34894972</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>23</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>23</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1475-6374</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>37</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal of enzyme inhibition and medicinal chemistry</Title>
          <ISOAbbreviation>J Enzyme Inhib Med Chem</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Repurposing FDA-approved sulphonamide carbonic anhydrase inhibitors for treatment of <i>Neisseria gonorrhoeae</i>.</ArticleTitle>
        <Pagination>
          <StartPage>51</StartPage>
          <EndPage>61</EndPage>
          <MedlinePgn>51-61</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/14756366.2021.1991336</ELocationID>
        <Abstract>
          <AbstractText><i>Neisseria gonorrhoeae</i> is a high-priority pathogen of concern due to the growing prevalence of resistance development against approved antibiotics. Herein, we report the anti-gonococcal activity of ethoxzolamide, the FDA-approved human carbonic anhydrase inhibitor. Ethoxzolamide displayed an MIC<sub>50,</sub> against a panel of <i>N. gonorrhoeae</i> isolates, of 0.125 µg/mL, 16-fold more potent than acetazolamide, although both molecules exhibited almost similar potency against the gonococcal carbonic anhydrase enzyme (NgCA) <i>in vitro</i>. Acetazolamide displayed an inhibition constant (<i>K</i><sub>i</sub>) versus NgCA of 74 nM, while Ethoxzolamide<sup>'</sup>s <i>K</i><sub>i</sub> was estimated to 94 nM. Therefore, the increased anti-gonococcal potency of ethoxzolamide was attributed to its increased permeability in <i>N. gonorrhoeae</i> as compared to that of acetazolamide. Both drugs demonstrated bacteriostatic activity against <i>N. gonorrhoeae</i>, exhibited post-antibiotic effects up to 10 hours, and resistance was not observed against both. Taken together, these results indicate that acetazolamide and ethoxzolamide warrant further investigation for translation into effective anti-<i>N. gonorrhoeae</i> agents.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Abutaleb</LastName>
            <ForeName>Nader S</ForeName>
            <Initials>NS</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biomedical Sciences and Pathobiology, Virginia-Maryland College of Veterinary Medicine, Virginia Polytechnic Institute and State University, Blacksburg, VI, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Elhassanny</LastName>
            <ForeName>Ahmed E M</ForeName>
            <Initials>AEM</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biomedical Sciences and Pathobiology, Virginia-Maryland College of Veterinary Medicine, Virginia Polytechnic Institute and State University, Blacksburg, VI, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nocentini</LastName>
            <ForeName>Alessio</ForeName>
            <Initials>A</Initials>
            <Identifier Source="ORCID">0000-0003-3342-702X</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of NEUROFARBA, Section of Pharmaceutical and Nutraceutical Sciences, University of Florence, Polo Scientifico, Firenze, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hewitt</LastName>
            <ForeName>Chad S</ForeName>
            <Initials>CS</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, Purdue University, West Lafayette, IN, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Elkashif</LastName>
            <ForeName>Ahmed</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Comparative Pathobiology, College of Veterinary Medicine, Purdue University, West Lafayette, IN, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cooper</LastName>
            <ForeName>Bruce R</ForeName>
            <Initials>BR</Initials>
            <AffiliationInfo>
              <Affiliation>Metabolite Profiling Facility, Bindley Bioscience Center, Purdue University, West Lafayette, Indiana, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Supuran</LastName>
            <ForeName>Claudiu T</ForeName>
            <Initials>CT</Initials>
            <Identifier Source="ORCID">0000-0003-4262-0323</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of NEUROFARBA, Section of Pharmaceutical and Nutraceutical Sciences, University of Florence, Polo Scientifico, Firenze, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Seleem</LastName>
            <ForeName>Mohamed N</ForeName>
            <Initials>MN</Initials>
            <Identifier Source="ORCID">0000-0003-0939-0458</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Biomedical Sciences and Pathobiology, Virginia-Maryland College of Veterinary Medicine, Virginia Polytechnic Institute and State University, Blacksburg, VI, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Center for Emerging, Zoonotic and Arthropod-borne Pathogens, Virginia Polytechnic Institute and State University, Blacksburg, VI, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Flaherty</LastName>
            <ForeName>Daniel P</ForeName>
            <Initials>DP</Initials>
            <Identifier Source="ORCID">0000-0002-8305-0606</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, Purdue University, West Lafayette, IN, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Purdue Institute for Drug Discovery, West Lafayette, IN, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Purdue Institute of Inflammation, Immunology and Infectious Disease, West Lafayette, IN, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>R01 AI148523</GrantID>
            <Acronym>AI</Acronym>
            <Agency>NIAID NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>J Enzyme Inhib Med Chem</MedlineTA>
        <NlmUniqueID>101150203</NlmUniqueID>
        <ISSNLinking>1475-6366</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D002257">Carbonic Anhydrase Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 4.2.1.1</RegistryNumber>
          <NameOfSubstance UI="D002256">Carbonic Anhydrases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>O3FX965V0I</RegistryNumber>
          <NameOfSubstance UI="D000086">Acetazolamide</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>Z52H4811WX</RegistryNumber>
          <NameOfSubstance UI="D005016">Ethoxzolamide</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000086" MajorTopicYN="N">Acetazolamide</DescriptorName>
          <QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName>
          <QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002257" MajorTopicYN="N">Carbonic Anhydrase Inhibitors</DescriptorName>
          <QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002256" MajorTopicYN="N">Carbonic Anhydrases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005016" MajorTopicYN="N">Ethoxzolamide</DescriptorName>
          <QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008826" MajorTopicYN="N">Microbial Sensitivity Tests</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015394" MajorTopicYN="N">Molecular Structure</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009344" MajorTopicYN="N">Neisseria gonorrhoeae</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013329" MajorTopicYN="N">Structure-Activity Relationship</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014486" MajorTopicYN="N">United States Food and Drug Administration</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Carbonic anhydrase inhibitors</Keyword>
        <Keyword MajorTopicYN="N">Neisseria gonorrhoeae</Keyword>
        <Keyword MajorTopicYN="N">antibiotics</Keyword>
        <Keyword MajorTopicYN="N">drug repurposing</Keyword>
      </KeywordList>
      <CoiStatement>No potential conflict of interest was reported by the author(s).</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>13</Day>
          <Hour>11</Hour>
          <Minute>26</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34894972</ArticleId>
        <ArticleId IdType="pmc">PMC8667909</ArticleId>
        <ArticleId IdType="doi">10.1080/14756366.2021.1991336</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Newman L, Rowley J, Vander HS, et al. . 
Global estimates of the prevalence and incidence of four curable sexually transmitted infections in 2012 based on systematic review and global reporting. PLOS One
2015;10:e0143304.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4672879</ArticleId>
            <ArticleId IdType="pubmed">26646541</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>World Health Organization . Multi-drug resistant gonorrhoea Fact Sheet. World Health Organization Fact Sheets. Geneva, Switzerland; 
2020. https://www.who.int/news-room/fact-sheets/detail/multi-drug-resistant-gonorrhoea</Citation>
        </Reference>
        <Reference>
          <Citation>Bowen VB, Braxton J, Davis DW, et al. . 
Sexually transmitted disease surveillance 2018. Atlanta (GA): Center for Disease Control and Prevention; 2019.</Citation>
        </Reference>
        <Reference>
          <Citation>Rice PA, Shafer WM, Ram S, Jerse AE.. 
Neisseria gonorrhoeae: drug resistance, mouse models, and vaccine development. Annual Rev Microbiol
2017;71:665–86.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28886683</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wi T, Lahra MM, Ndowa F, et al. . 
Antimicrobial resistance in Neisseria gonorrhoeae: Global surveillance and a call for international collaborative action. PLOS Med
2017;14:e1002344–16.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5501266</ArticleId>
            <ArticleId IdType="pubmed">28686231</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Derbie A, Mekonnen D, Woldeamanuel Y, Abebe T.. 
Azithromycin resistant gonococci: a literature review. Antimicrob Resist Infect Control
2020;9:1–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7436955</ArticleId>
            <ArticleId IdType="pubmed">32811545</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gernert KM, Seby S, Schmerer MW, et al. . 
Azithromycin susceptibility of Neisseria gonorrhoeae in the USA in 2017: a genomic analysis of surveillance data. Lancet Microbe
2020;1:e154–e164.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7527259</ArticleId>
            <ArticleId IdType="pubmed">33005903</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cyr SS, Barbee L, Workowski KA, et al. . 
Update to CDC's treatment guidelines for gonococcal infection, 2020. MMWR Morb Mortal Wkly Rep
2020;69:1911–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7745960</ArticleId>
            <ArticleId IdType="pubmed">33332296</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fifer H, Natarajan U, Jones L, et al. . 
Failure of dual antimicrobial therapy in treatment of gonorrhea. New Engl J Med
2016;374:2504–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27332921</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cámara J, Serra J, Ayats J, et al. . 
Molecular characterization of two high-level ceftriaxone-resistant Neisseria gonorrhoeae isolates detected in Catalonia, Spain. J Antimicrob Chemother
2012;67:1858–60.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22566592</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Golparian D, Ohlsson AK, Janson H, et al. . 
Four treatment failures of pharyngeal gonorrhoea with ceftriaxone (500 mg) or cefotaxime (500 mg), Sweden, 2013 and 2014. Eurosurveillance
2014;19:20862.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25108533</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Centers for Disease Control and Prevention . Antibiotic resistance threats in the United States, 2019. Atlanta, GA: U.S. Department of Health and Human Services; 
2019. https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf</Citation>
        </Reference>
        <Reference>
          <Citation>Bolan G, Sparling PF, Wasserheit JN.. 
The emerging threat of untreatable gonococcal infection. N Engl J Med
2012;366:485–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22316442</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Farha MA, Brown ED.. 
Drug repurposing for antimicrobial discovery. Nat Microbiol
2019;4:565–77.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30833727</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ashburn TT, Thor KB.. 
Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov
2004;3:673–83.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15286734</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chong CR, Sullivan DJ Jr.. 
New uses for old drugs. Nature
2007;448:645–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17687303</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takeuchi H, Supuran C, Onishi S, Nishimori I.. 
The alpha and beta classes carbonic anhydrases from Helicobacter pylori as novel drug targets. Current Pharmaceutical Design
2008;14:622–30.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18336307</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rahman MM, Tikhomirova A, Modak JK, et al. . 
Antibacterial activity of ethoxzolamide against Helicobacter pylori strains SS1 and 26695. Gut Pathogens
2020;12:20–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7158114</ArticleId>
            <ArticleId IdType="pubmed">32318117</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Modak JK, Tikhomirova A, Gorrell RJ, et al. . 
Anti-Helicobacter pylori activity of ethoxzolamide. J Enzyme Inhib Med Chem
2019;34:1660–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6759998</ArticleId>
            <ArticleId IdType="pubmed">31530039</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sanders E, Maren TH.. 
Inhibition of carbonic anhydrase in Neisseria: effects on enzyme activity and growth. Mol Pharmacol
1967;3:204–15.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">4962249</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nafi BM, Miles RJ, Butler LO, et al. . 
Expression of carbonic anhydrase in neisseriae and other heterotrophic bacteria. J Med Microbiol
1990;32:1–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2111405</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Johnson BK, Colvin CJ, Needle DB, et al. . 
The carbonic anhydrase inhibitor ethoxzolamide inhibits the Mycobacterium tuberculosis PhoPR regulon and Esx-1 secretion and attenuates virulence. Antimicrobial Agents Chemother
2015;59:4436–45.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4505220</ArticleId>
            <ArticleId IdType="pubmed">25987613</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Supuran CT, Capasso C.. 
Antibacterial carbonic anhydrase inhibitors: an update on the recent literature. Expert Opin Ther Pat
2020;30:963–82.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32806966</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Supuran CT.
Bacterial carbonic anhydrases as drug targets: toward novel antibiotics?
Front Pharmacol
2011;2:34–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3132667</ArticleId>
            <ArticleId IdType="pubmed">21779249</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Capasso C, Supuran CT.. 
An overview of the alpha-, beta- and gamma-carbonic anhydrases from Bacteria: Can bacterial carbonic anhydrases shed new light on evolution of bacteria?
J Enzyme Inhib Med Chem
2015;30:325–32.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24766661</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Modak JK, Modakh JK, Liu YC, et al. . 
Structural basis for the inhibition of Helicobacter pylori α-carbonic anhydrase by sulfonamides. PLOS ONE
2015;10:e0127149.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4444264</ArticleId>
            <ArticleId IdType="pubmed">26010545</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Modak JK, Liu YC, Supuran CT, Roujeinikova A.. 
Structure-activity relationship for sulfonamide inhibition of Helicobacter pylori α-carbonic anhydrase. J Med Chem
2016;59:11098–109.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28002963</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mancuso F, De Luca L, Angeli A, et al. . 
In silico-guided identification of new potent inhibitors of carbonic anhydrases expressed in Vibrio cholerae. ACS Med Chem Letters
2020;11:2294–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7667831</ArticleId>
            <ArticleId IdType="pubmed">33214843</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Del Prete S, Nocentini A, Supuran CT, Capasso C.. 
Bacterial ι-carbonic anhydrase: a new active class of carbonic anhydrase identified in the genome of the Gram-negative bacterium Burkholderia territorii. J Enzyme Inhib Med Chem
2020;35:1060–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7191908</ArticleId>
            <ArticleId IdType="pubmed">32314608</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Del Prete S, Vullo D, Di P, et al. . 
Sulfonamide inhibition profile of the γ-carbonic anhydrase identified in the genome of the pathogenic bacterium Burkholderia pseudomallei the etiological agent responsible of melioidosis. Bioorganic Med Chem Letters
2017;27:490–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28025002</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Burghout P, Cron LE, Gradstedt H, et al. . 
Carbonic anhydrase is essential for Streptococcus pneumoniae growth in environmental ambient air. J Bacteriol
2010;192:4054–62.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2916381</ArticleId>
            <ArticleId IdType="pubmed">20525828</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Supuran CT, Capasso C.. 
An overview of the bacterial carbonic anhydrases. Metabolites
2017;7:56–2139.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5746736</ArticleId>
            <ArticleId IdType="pubmed">29137134</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Capasso C, Supuran CT.. 
Bacterial, fungal and protozoan carbonic anhydrases as drug targets. Expert Opin Ther Targets
2015;19:1689–704.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26235676</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kaur J, Cao X, Abutaleb NS, et al. . 
Optimization of acetazolamide-based scaffold as potent inhibitors of vancomycin-resistant enterococcus. J Med Chem
2020;63:9540–62.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8317130</ArticleId>
            <ArticleId IdType="pubmed">32787141</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abutaleb NS, Elkashif A, Flaherty DP, Seleem MN.. 
In vivo antibacterial activity of acetazolamide. Antimicrob Agents Chemother
2021;65:e01715–e01720.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8097480</ArticleId>
            <ArticleId IdType="pubmed">33495225</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abutaleb NS, Elhassanny AEM, Flaherty DP, Seleem MN.. 
In vitro and in vivo activities of the carbonic anhydrase inhibitor, dorzolamide, against vancomycin-resistant enterococci. PeerJ
2021;9:e11059.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8018244</ArticleId>
            <ArticleId IdType="pubmed">33850651</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hewitt CS, Abutaleb NS, Elhassanny AEM, et al. . 
Structure-activity relationship studies of acetazolamide-based carbonic anhydrase inhibitors with activity against Neisseria gonorrhoeae. ACS Infect Dis
2021;7:1969–84.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8317129</ArticleId>
            <ArticleId IdType="pubmed">33765392</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Drance SM.
Ethoxzolamide (cardrase) in the management of chronic simple glaucoma. Arch Ophthalmol
1960;64:433–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">13817990</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maren TH, Brechue WF, Bar-Ilan A.. 
Relations among IOP reduction, ocular disposition and pharmacology of the carbonic anhydrase inhibitor ethoxzolamide. Exp Eye Res
1992;55:73–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1397133</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Supuran CT, Altamimi ASA, Carta F.. 
Carbonic anhydrase inhibition and the management of glaucoma: a literature and patent review 2013-2019. Expert Opin Ther Pat
2019;29:781–92.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31596641</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gordon DM.
Ethoxzolamide; a new carbonic anhydrase inhibitor. Am J Ophthalmol
1958;46:41–4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">13545308</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lim L, Foldvary N, Mascha E, Lee J.. 
Acetazolamide in women with catamenial epilepsy. Epilepsia
2001;42:746–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11422329</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Patsalos PN.
The epilepsy prescriber’s guide to antiepileptic drugs. Cambridge (UK): Cambridge University Press; 2018.</Citation>
        </Reference>
        <Reference>
          <Citation>Van Berkel MA, Elefritz JL.. 
Evaluating off-label uses of acetazolamide. Bull Am Soc Hosp Pharm
2018;75:524–31.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29626002</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ritschel WA, Paulos C, Arancibia A, et al. . 
Pharmacokinetics of acetazolamide in healthy volunteers after short- and long-term exposure to high altitude. J Clin Pharmacol
1998;38:533–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9650543</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Low EV, Avery AJ, Gupta V, et al. . 
Identifying the lowest effective dose of acetazolamide for the prophylaxis of acute mountain sickness: systematic review and meta-analysis. BMJ
2012;345:e6779.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3475644</ArticleId>
            <ArticleId IdType="pubmed">23081689</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>World Health Organization . WHO Model List of Essential Medicines. Essential medicines and health products. 2017; (August):1–39.</Citation>
        </Reference>
        <Reference>
          <Citation>Dollery CT, Boobis AR.. 
Therapeutic drugs, 2nd Ed. London (UK): Churchill Livingstone; 1999.</Citation>
        </Reference>
        <Reference>
          <Citation>Ten Hove MW, Friedman DI, Patel AD, Irrcher I, et al. . 
Safety and tolerability of acetazolamide in the idiopathic intracranial hypertension treatment trial. J Neuro-Ophthalmol
2016;36:13–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26587993</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lubow M, Kuhr L.. 
Pseudotumor cerebri: comments on practical management. Neuro-ophthalmology
1976;9:199–206.</Citation>
        </Reference>
        <Reference>
          <Citation>Tomsak RL, Niffenegger AS, Remler BF.. 
Treatment of pseudotumor cerebri with Diamox (acetazolamide). J Neuro-Ophthalmol
1988;8:93–8.</Citation>
        </Reference>
        <Reference>
          <Citation>Hampson AJ, Babalonis S, Lofwall MR, et al. . 
A pharmacokinetic study examining acetazolamide as a novel adherence marker for clinical trials. J Clin Psychopharmacol
2016;36:324–32.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5360176</ArticleId>
            <ArticleId IdType="pubmed">27300254</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wistrand PJ.
The use of carbonic anhydrase inhibitors in ophthalmology and clinical medicine. Annals NY Acad Sci
1984;429:609–19.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6588916</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wistrand PJ, Rawls JA Jr, Maren TH.. 
Sulphonamide carbonic anhydrase inhibitors and intra-ocular pressure in rabbits. A comparison between in vitro and in vivo activities based on tissue distributions and physical and chemical properties of nine compounds. Acta Pharmacol Toxicol
1961;17:337–55.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">13786041</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wallace SM, Reigelman S.. 
Uptake of acetazolamide by human erythrocytes in vitro. J Pharm Sci
1977;66:729–31.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">874760</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wallace SM, Shah VP, Riegelman S.. 
GLC analysis of acetazolamide in blood, plasma, and saliva following oral administration to normal subjects. J Pharm Sci
1977;66:527–30.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">856972</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Friedland BR, Maren TH, Carbonic anhydrase: pharmacology of inhibitors and treatment of glaucoma. In: Pharmacology of the Eye. Handbook of experimental pharmacology, vol. 69. Berlin, Heidelberg: Springer; 1984. p. 279–309.</Citation>
        </Reference>
        <Reference>
          <Citation>Alhashimi M, Mayhoub A, Seleem MN.. 
Repurposing salicylamide for combating multidrug-resistant Neisseria gonorrhoeae. Antimicrob Agents Chemother
2019;63:e01225–19.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6879211</ArticleId>
            <ArticleId IdType="pubmed">31570391</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Seong YJ, Alhashimi M, Mayhoub A, et al. . 
Repurposing fenamic acids drugs to combat multidrug-resistant Neisseria gonorrhoeae. Antimicrob Agents Chemother
2020;64:e02206–19.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7318036</ArticleId>
            <ArticleId IdType="pubmed">32393483</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Elkashif A, Seleem MN.. 
Investigation of auranofin and gold-containing analogues antibacterial activity against multidrug-resistant Neisseria gonorrhoeae. Sci Rep
2020;10:5602–10.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7101410</ArticleId>
            <ArticleId IdType="pubmed">32221472</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Petreni A, De Luca V, Scaloni A, et al. . 
Anion inhibition studies of the Zn(II)-bound ι-carbonic anhydrase from the gram-negative bacterium Burkholderia territorii. J Enzyme Inhib Med Chem
2021;36:372–6..</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7782983</ArticleId>
            <ArticleId IdType="pubmed">33390061</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vullo D, Del Prete S, Osman SM, et al. . 
Sulfonamide inhibition studies of the γ-carbonic anhydrase from the oral pathogen Porphyromonas gingivalis. Bioorganic Med Chem Lett
2014;24:240–4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24316122</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Turkmen H, Durgun M, Yilmaztekin S, et al. . 
Carbonic anhydrase inhibitors. Novel sulfanilamide/acetazolamide derivatives obtained by the tail approach and their interaction with the cytosolic isozymes I and II, and the tumor-associated isozyme IX. Bioorganic Med Chem Lett
2005;15:367–72.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15603956</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Di Cesare Mannelli L, Micheli L, Carta F, et al. . 
Carbonic anhydrase inhibition for the management of cerebral ischemia: in vivo evaluation of sulfonamide and coumarin inhibitors. J Enzyme Inhib Med Chem
2016;31:894–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26607399</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nocentini A, Hewitt CS, Mastrolorenzo MD, et al. . 
Anion inhibition studies of the α-carbonic anhydrases from Neisseria gonorrhoeae. J Enzyme Inhib Med Chem
2021;36:1061–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8158254</ArticleId>
            <ArticleId IdType="pubmed">34030562</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yung-Chi C, Prusoff WH.. 
Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol
1973;22:3099–108.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">4202581</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hamann HJ, Abutaleb NS, Pal R, et al. . 
β,γ-Diaryl α-methylene-γ-butyrolactones as potent antibacterials against methicillin-resistant Staphylococcus aureus. Bioorganic Chem
2020;104:104183–90.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32971415</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Elsebaei MM, Abutaleb NS, Mahgoub AA, et al. . 
Phenylthiazoles with nitrogenous side chain: an approach to overcome molecular obesity. Eur J Med Chem
2019;182:111593–603.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31446245</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abutaleb NS, Seleem MN.. 
Repurposing the antiamoebic drug diiodohydroxyquinoline for treatment of Clostridioides difficile infections. Antimicrob Agents Chemother
2020;64:e02115–19.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7269495</ArticleId>
            <ArticleId IdType="pubmed">32253206</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Richter MF, Drown BS, Riley AP, et al. . 
Predictive compound accumulation rules yield a broad-spectrum antibiotic. Nature
2017;545:299–304.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5737020</ArticleId>
            <ArticleId IdType="pubmed">28489819</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Parker EN, Drown BS, Geddes EJ, et al. . 
Implementation of permeation rules leads to a FabI inhibitor with activity against gram-negative pathogens. Nat Microbiol
2020;5:67–75.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6953607</ArticleId>
            <ArticleId IdType="pubmed">31740764</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mohammad H, Abutaleb NS, Dieterly AM, et al. . 
Evaluation of ebselen in resolving a methicillin-resistant Staphylococcus aureus infection of pressure ulcers in obese and diabetic mice. PLOS One
2021;16:e0247508.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7899319</ArticleId>
            <ArticleId IdType="pubmed">33617589</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shahin IG, Abutaleb NS, Alhashimi M, et al. . 
Evaluation of N-phenyl-2-aminothiazoles for treatment of multi-drug resistant and intracellular Staphylococcus aureus infections. Eur J Med Chem
2020;202:112497.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32707373</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pankuch GA, Jacobs MR, Appelbaum PC.. 
Postantibiotic effects of garenoxacin (BMS-284756) against 12 gram-positive or -negative organisms. Antimicrob Agents Chemother
2003;47:1140–2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC149305</ArticleId>
            <ArticleId IdType="pubmed">12604557</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Butler MM, Waidyarachchi SL, Connolly KL, et al. . 
Aminomethyl spectinomycins as therapeutics for drug-resistant gonorrhea and chlamydia coinfections. Antimicrob Agents Chemother
2018;62:e00325–18.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5923137</ArticleId>
            <ArticleId IdType="pubmed">29483122</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Naclerio GA, Abutaleb NS, Li D, et al. . 
Ultrapotent inhibitor of clostridioides difficile growth, which suppresses recurrence in vivo. J Med Chem
2020;63:11934–44.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32960605</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thangamani S, Mohammad H, Abushahba MFN, et al. . 
Antibacterial activity and mechanism of action of auranofin against multi-drug resistant bacterial pathogens. Sci Rep
2016;6:22571.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4776257</ArticleId>
            <ArticleId IdType="pubmed">26936660</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chirică LC, Elleby B, Jonsson BH, Lindskog S.. 
The complete sequence, expression in Escherichia coli, purification and some properties of carbonic anhydrase from Neisseria gonorrhoeae. Eur J Biochem
1997;244:755–60.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9108244</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Perry TR, Schentag JJ.. 
Clinical use of ceftriaxone. Clin Pharmacokinet
2001;40:685–94.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11605716</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Spivey JM.
The postantibiotic effect. Clin Pharm
1992;11:865–75.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1341993</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cars O, Odenholt-Tornqvist I.. 
The post-antibiotic sub-MIC effect in vitro and in vivo. J Antimicrob Chemother
1993;31:159–66.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8335517</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mohammad H, Abutaleb NS, Seleem MN.. 
Auranofin rapidly eradicates methicillin-resistant Staphylococcus aureus (MRSA) in an infected pressure ulcer mouse model. Sci Rep
2020;10:7251–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7190694</ArticleId>
            <ArticleId IdType="pubmed">32350417</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Binet R, Maurelli AT.. 
Frequency of development and associated physiological cost of azithromycin resistance in Chlamydia psittaci 6BC and C. trachomatis L2. Antimicrob Agents Chemother
2007;51:4267–75.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2167982</ArticleId>
            <ArticleId IdType="pubmed">17908942</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Supuran CT.
Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discovery
2008;7:168–81.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18167490</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Woods DD.
The relation of p-aminobenzoic acid to the mechanism of the action of sulphanilamide. Br J Exp Pathol
1940;21:74–90.</Citation>
        </Reference>
        <Reference>
          <Citation>Davis TD, Gerry CJ, Tan DS.. 
General platform for systematic quantitative evaluation of small-molecule permeability in bacteria. ACS Chem Biol
2014;9:2535–44.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4245172</ArticleId>
            <ArticleId IdType="pubmed">25198656</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao S, Adamiak JW, Bonifay V, et al. . 
Defining new chemical space for drug penetration into gram-negative bacteria. Nat Chem Biol
2020;16:1293–302.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7897441</ArticleId>
            <ArticleId IdType="pubmed">33199906</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Richter MF, Hergenrother PJ.. 
The challenge of converting gram-positive-only compounds into broad-spectrum antibiotics. Annals NY Acad Sci
2019;1435:18–38.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6093809</ArticleId>
            <ArticleId IdType="pubmed">29446459</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>O'Shea R, Moser HE.. 
Physicochemical properties of antibacterial compounds: implications for drug discovery. J Med Chem
2008;51:2871–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18260614</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cowan SW, Garavito RM, Jansonius JN, et al. . 
The structure of OmpF porin in a tetragonal crystal form. Structure
1995;3:1041–50.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8589999</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zeth K, Kozjak-Pavlovic V, Faulstich M, et al. . 
Structure and function of the PorB porin from disseminating Neisseria gonorrhoeae. Biochem J
2013;449:631–42.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23095086</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Danelon C, Suenaga A, Winterhalter M, Yamato I.. 
Molecular origin of the cation selectivity in OmpF porin: single channel conductances vs. free energy calculation. Biophys Chem
2003;104:591–603.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12914905</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Acosta-Gutiérrez S, Ferrara L, Pathania M, et al. . 
Getting drugs into gram-negative bacteria: rational rules for permeation through general porins. ACS Infect Dis
2018;4:1487–98.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29962203</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Olesky M, Zhao S, Rosenberg RL, Nicholas RA.. 
Porin-mediated antibiotic resistance in Neisseria gonorrhoeae: ion, solute, and antibiotic permeation through PIB proteins with penB mutations. J Bacteriol
2006;188:2300–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1428387</ArticleId>
            <ArticleId IdType="pubmed">16547016</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maynard RL.
The Merck index: 1996. Occup Environ Med
1997;54:288.</Citation>
        </Reference>
        <Reference>
          <Citation>Remko M, Von Der Lieth CW.. 
Theoretical study of gas-phase acidity, pKa, lipophilicity, and solubility of some biologically active sulfonamides. Bioorg Med Chem
2004;12:5395–5403.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15388166</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
